In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.

Annals of internal medicine2025PMID: 41052437

View on PubMed DOI: 10.7326/ANNALS-25-03745-JC

Plain Language Summary

This study showed that weekly subcutaneous cagrilintide-semaglutide combination increased weight loss at 68 weeks in adults with overweight or obesity. The dual amylin/GLP-1 approach achieved greater reduction than either agent alone.

Abstract

GIM/FP/GP: [Formula: see text].

Authors

Agarwal, Arnav; Padwal, Raj